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Thrombocytopenia is a well-recognized idiosyn-
cratic reaction associated with the administration of
heparin.1,2 To our knowledge, the combination of
an anaphylactic reaction in response to heparin with
acute heparin-induced thrombocytopenia has not
been previously reported. We recently observed a
patient with this combination of findings. The
patient was documented to have antibodies capable
of releasing serotonin from platelets in the presence
of heparin and of reacting with heparin and with
heparin platelet factor 4 (PF4) complexes. The clin-
ical presentation and laboratory study results sug-
gested that concurrent anaphylaxis and severe
thrombocytopenia after injection of heparin were
caused by two antibodies, one specific for heparin
PF4 complexes and the other a mast cell–associated
immunoglobulin E (IgE) antibody specific for
heparin. However, it was not possible to rule out the
possibility that both immunologic processes were
mediated by the same heparin-induced antibody. 
CASE REPORT
A 48-year-old man was admitted to the neurosurgical
service of Tulane University Hospital with a 3-day history
of fever, nausea, diaphoresis, and right lower facial and
neck pain. Two weeks earlier, the patient had undergone a
lumbar laminectomy and lumbar spinal fusion during
which a right internal jugular catheter was placed. The
patient’s history included a prior lumbar laminectomy and
an arthroscopic examination of the right knee. Previous
exposure to heparin was documented. The patient had
undergone heparin treatment through a flush solution used
to maintain patency of an arterial line and also through the
circuitry for autotransfusion of shed blood during the
recent lumbar laminectomy. Medications included
hydrocodone bitartrate, acetaminophen, cyclobenzaprine
hydrochloride, lorazepam, and alprazolam.
Physical examination revealed a blood pressure of
130/80 mm Hg, a heart rate of 86 beats/min, respira-
tions at 16 breaths/min, and a body temperature of 38°C.
The right side of the neck was markedly swollen and
exquisitely tender to palpation. No swelling was detected
in either upper extremity.
A diagnosis was made of thrombophlebitis of the right
internal jugular vein, with the possibility of suppurative or
septic phlebitis and soft tissue abscess. A magnetic resonance
angiography confirmed complete thrombosis of the cervical
right internal jugular vein without intracranial extension.
However, extension was observed into the innominate vein
and central part of the right subclavian vein, although com-
plete occlusion was not apparent in either of these veins. The
findings were compatible with inflammatory changes at
about the middle one third of the internal jugular vein.
Later, venous duplex study results confirmed the findings in
the right jugular and subclavian veins.
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We report the occurrence of acute heparin-induced thrombocytopenia in a patient with
anaphylaxis that began immediately after an intravenous bolus dose of unfractionated
heparin. This case report is the first to document the concurrence of these 2 reactions to
heparin. An abrupt fall in platelet count was documented immediately after the anaphy-
lactic response. Study results for antibodies characteristic of heparin-induced thrombo-
cytopenia were positive in 2 assays: serotonin release assay and heparin platelet factor 4
enzyme-linked immunosorbent assay. The patient’s antibody was exclusively
immunoglobulin G. Any explanation for the relationship between the antibody response
observed and the histamine release remains speculative. (J Vasc Surg 1998;28:561-5)
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Intravenous doses of vancomycin hydrochloride (800
mg) and ceftriaxone sodium (1 g) at every 12 hours were
begun promptly. A left subclavian catheter was placed, and
the findings of a chest radiograph were not remarkable.
Blood cultures were obtained but subsequently did not
yield organisms. A 10,000-unit bolus of porcine heparin
sodium (Wyeth-Ayerst Laboratories, Inc, Radnor, Pa) was
given intravenously through the left subclavian line, and
heparin was administered by constant infusion at 1000
units/hr. Almost immediately after the heparin bolus was
administered, the patient complained to the nurses about
difficulty in breathing. He became anxious, diaphoretic,
agitated, and confused; then he suddenly stopped breath-
ing. Respiratory arrest was accompanied by the apparent
cessation of previously palpable peripheral pulses for a few
moments. The patient’s fingers were blue and mottled,
although his feet appeared flushed and hyperemic. He
responded promptly to sternal compression and the
administration of 100% oxygen. Heparin anaphylaxis
promptly was considered, and the patient underwent no
further heparin therapy throughout his course of treat-
ment. During 5 minutes of cardiopulmonary resuscitation,
the patient’s pulse and respiration spontaneously returned,
and no pharmacologic agents were required. The arterial
blood gases and the biochemical profile were not abnor-
mal. A chest radiograph was essentially unchanged from
the previous one taken after the subclavian line placement.
Although an acute allergic reaction to heparin was consid-
ered likely, a perfusion-ventilation lung scan was done
promptly and excluded pulmonary embolism. The
patient’s condition remained stable, and he was trans-
ferred to the Coronary Care Unit. The patient’s condition
continued to improve in the hospital, while he remained
being treated with warfarin and vancomycin. He was dis-
charged from the hospital still taking those medications.
Warfarin treatment was continued for approximately 6
months. 
Laboratory studies at the patient’s admission to the
hospital had revealed the following: a hematocrit value of
32%, a red blood cell count of 3.5 · 106/m L, a hemoglo-
bin concentration of 11.8 g/dL, a white blood cell count
of 9600/m L, with 74% neutrophils, 16% lymphocytes, 9%
monocytes, and 1% eosinophils. The platelet count was
178,000/ m L. The prothrombin time, the international
normalized ratio, and the partial thromboplastin time
were within normal limits. Additional blood studies were
conducted after the patient was transferred to the
Coronary Care Unit. The results of these tests were essen-
tially unchanged from previous values, with the exception
of an increase in the blood glucose level to 177 mg/dL
and a decrease in the platelet count to 45,000/m L as com-
pared with 178,000/ m L a few hours earlier (Fig. 1).
Assays for fibrinogen and fibrin split products were not
suggestive of consumptive coagulopathy. Warfarin therapy
was begun several hours after the patient’s admission to
the Coronary Care Unit but after the samples for the
coagulation studies had been obtained. Four hours after
the documented fall in platelet count, the count 
rose to 73,000/ m L, and after 5 hours, the count had
reached 103,000/ m L. Within 24 hours, the count was
159,000/m L, after which it remained within normal lim-
its. Studies for antibodies characteristic of heparin-induced
thrombocytopenia were done on a blood sample drawn
within 20 hours of the anaphylactic reaction and were per-
formed at the Blood Center of Southeastern Wisconsin,
Inc (Milwaukee, Wis). Positive results were obtained in
the serotonin release test3 and the heparin PF4 enzyme-
linked immunosorbent assay (ELISA).4 With Ig class-spe-
cific probes in ELISA,5 the patient’s antibody was found
to be exclusively IgG, with a titer of about 1:50. No IgM,
IgA, or IgE antibodies were detected.
Because of the relatively young age of the patient and
the unusual location of the thrombosis, a workup for a
thrombophilic disorder was completed after all warfarin
was discontinued. Protein C, protein S, and antithrombin
III levels were within normal limits, as were anticardiolipin
antibody levels and thrombin time. The protein S func-
tional assay was performed at the Associated Regional and
University Pathologists, Inc (Salt Lake City, Utah).
Analysis by polymerase chain reaction did not show a fac-
tor V Leiden mutation. The patient’s condition has
remained stable without recurrence of thrombotic events
for approximately 18 months after the reaction to heparin
and for approximately 1 year after cessation of warfarin
therapy.
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Fig. 1. Graph shows abrupt fall in platelet count during
acute anaphylaxis after intravenous bolus unfractionated
heparin treatment.
DISCUSSION
Thrombocytopenia is a well-recognized idiosyn-
cratic reaction associated with the administration of
heparin. The occurrence may be asymptomatic.1,2 It
probably occurs more often with heparin derived
from bovine lung than with heparin derived from
porcine gut.1 A potentially fulminant and sometimes
lethal extreme of this reaction is the heparin-induced
thrombocytopenia and thrombosis syndrome
(HITT). Thromboembolism resulting from expo-
sure to heparin6,7 was recognized even before the
syndrome was more precisely described in 1973.8
HITT is thought to be mediated by Igs that activate
platelets in the presence of heparin. Recent reports
have shown that these antibodies are specific not for
heparin itself but for complexes formed between
heparin and PF4, a basic heparin-binding protein
found normally in platelet alpha granules.4,9 These
antibodies can be of the IgG, IgM, or IgA classes.5,9
A hypothesis has been offered to explain how the
antibodies cause platelet activation, thrombocytope-
nia, and vascular injury predisposed to thrombosis.4
Warkentin et al10 described 6 cases of acute sys-
temic reactions to intravenous bolus heparin associat-
ed with an abrupt fall in platelet count. The systemic
symptoms included fever, hypertension, chills or rig-
ors, tachycardia, diaphoresis, and nausea and flush-
ing. Clinically, these reactions appeared to resemble
severe acute febrile transfusion reactions. All patients
had undergone heparin therapy, usually by subcuta-
neous route, before the bolus that precipitated the
acute reaction. These observations showed that acute
systemic reactions after a bolus dose of intravenous
heparin can be associated with acute heparin-induced
thrombocytopenia.
Only a few cases of anaphylaxis after treatment
with heparin have been described.11-13 To our
knowledge, the combination of anaphylactic reac-
tion in response to heparin and acute heparin-
induced thrombocytopenia has not been reported
previously.
The patient had a severe anaphylactic reaction,
and acute thrombocytopenia developed after unfrac-
tionated heparin was given by intravenous infusion.
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Fig. 2. Model proposed to explain thrombocytopenia and thrombosis that occur when
patients with antibodies specific for heparin and platelet factor 4 (PF4) complexes are exposed
to heparin. Injected heparin (1) binds to small quantities of PF4 normally found on endothe-
lial cells associated with glycosaminoglycan (2) or released from platelets by the direct action
of heparin, which leads to formation of heparin and PF4 complexes (3). These complexes react
with antibodies to form immune complexes (4) that interact with platelet Fc receptors to cause
release of additional PF4 (5). The released PF4 binds to free heparin and, subsequently, to anti-
bodies to form additional immune complexes, establishing a cycle of platelet activation (6).
PF4 released in excess of the amount that can bind to available heparin reacts with gly-
cosaminoglycan on endothelial cells to provide targets for antibody binding (7) and to set the
stage for antibody-mediated endothelial cell injury predisposing to thrombosis.15
Platelet counts obtained before and after the reac-
tion showed that most of the platelets in the periph-
eral blood were destroyed quickly or sequestered at
exposure to heparin. The destruction of platelets in
HITT is known to be a consequence of platelet acti-
vation caused by immune complexes consisting of
heparin, PF4, and IgG antibodies.4
The serotonin release test is based on the ability
of patient serum containing heparin-induced anti-
bodies to release radiolabeled serotonin from sero-
tonin-loaded normal platelets in the presence of low
doses of heparin (0.1 U/mL) on incubation at 37°C
with gentle stirring. Specificity is established by
showing inhibition of release at high-dose heparin
(100 U/mL).3 The heparin PF4 ELISA is conduct-
ed by preparing complexes of heparin and the
platelet-derived heparin-binding protein, PF4, at
optimal ratios of the 2 substances. The complexes are
plated in the wells of a polystyrene microtiter tray and
are used as targets for antibodies. Antibodies that
bind to these complexes are detected with ELISA
with an alkaline phosphatase-labeled secondary
probe specific for human IgG/IgM.4 As with the
serotonin release test, specificity of a reaction is con-
firmed by showing inhibition of antibody binding at
higher concentrations of heparin. The serotonin
release test is more sensitive than the commonly used
platelet aggregation test,14 and the heparin PF4
ELISA, in turn, is more sensitive than the serotonin
release test for antibody detection.4
Recent study results have shown that antibodies
associated with HITT are specific for complexes
formed between heparin and PF4.15 It has been
hypothesized4 that thrombocytopenia and throm-
bosis in patients with heparin sensitivity can be
explained by the following sequence of events: (1)
injected heparin reacts with the PF4 normally found
on the surface of endothelial cells to form heparin
PF4 complexes; (2) these complexes react with the
antibody to form immune complexes; (3) immune
complexes formed on or near the surface of circulat-
ing platelets react with platelet Fc receptors to pro-
mote platelet activation, which causes release of PF4
from platelet storage granules; (4) the released PF4
reacts with heparin and the antibody to form addi-
tional immune complexes; (5) these complexes pro-
mote future platelet activation and PF4 release,
which sets up a cycle that leads to platelet destruc-
tion; and (6) after the injected heparin is cleared,
PF4 reassociates with heparin-like glycosaminogly-
can molecules on the surface of the endothelial cells
to provide targets for antibody binding, which sets
the stage for endothelial cell injury and predisposes
a patient to thrombosis. The sequence of events is
illustrated in Fig. 2. Microparticles with procoagu-
lant activity released from activated platelets may
also contribute to the thrombotic tendency.16
Thrombocytopenia and thrombosis that occur in
patients with heparin sensitivities are not ordinarily
associated with respiratory distress or anaphylaxis.
Although human platelets do not contain histamine,
the pulmonary symptoms of our patient were possibly
the result of intravascular platelet aggregation, the
trapping of the aggregates in pulmonary capillaries,
and the release of vasoactive substances, such as sero-
tonin. PF4 is a member of the chemokine family of
proteins, and certain chemokines are potent releasers
of histamine from mast cells.17 However, PF4 has not
been shown to share this property. The immune com-
plexes consisting of heparin, PF4, and IgG antibody
could have triggered widespread activation of com-
plement in the patient’s circulation, which would have
lead to production of complement-derived anaphylo-
toxin.18 However, pulmonary distress and anaphylax-
is of the severity seen in this case have not previously
been described in patients with heparin-induced anti-
bodies who are given heparin. We favor the possibili-
ty that 2 distinct pathologic processes were at work in
this patient—the thrombocytopenia was caused by
antibodies specific for heparin PF4 complexes, which
acted according to the scheme described above, and
the anaphylaxis was caused by a mast cell–associated
heparin-specific IgE antibody, which was induced by
the patient’s prior exposures to heparin.
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